The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EMN 2018 | Novel avenues for MM treatment: CAR T-cells, venetoclax, induction & MRD
Nikhil Munshi
• 19 Apr 2018
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting novel avenues for multiple myeloma (MM) therapy from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy. Dr Munshi covers BCMA-targeting CAR T-cells, venetoclax, induction regimens and measurable residual disease monitoring.
